科学杂志报道巴西科兴疫苗对于P.1病毒的一针有效性49.6%

billwanhua

本站元老
注册
2005-07-07
消息
5,404
荣誉分数
1,627
声望点数
373

key takeaways:
  1. 49.6% real-world effectiveness for P.1 variant after only 1 shot. It’s also not clear how well the mRNA vaccines protect against the P.1 variant. The efficacy is based on assumption that P. 1 makes up most of the positive cases.
  2. “Probably the effectiveness will be higher than the preliminary study is showing,”, vaccine effectiveness in Brazil may produce artificially low results because there is a high risk that people have some immunity because of previous contact with the virus. 实际有效率可能更高因为实验的地方以前是传染重灾区,可能很多人以前接触过病毒本身已经有一定免疫
  3. The study’s preliminary results, not yet peer reviewed, were posted to a preprint server yesterday and are the first to assess the effectiveness of the vaccine made by Sinovac Biotech in an area flooded with the P.1 variant.
sidenote: 最近有智利实验的报道,同样的疫苗有完全不同的结论,一针的有效性几乎没有作用,智利会在未来一周左右出最终的报告。
 
最后编辑:
顶部